Special Issue

Flaviviruses and Flavivirus Vaccines

Message from the Guest Editor

The Flaviviruses represent a family of positive, single-stranded, enveloped RNA viruses which can be transmitted by arthropods such as mosquitoes and ticks. It includes the Yellow Fever virus, Dengue virus, Japanese encephalitis, West Nile viruses, and Zika virus. Flaviviruses are now globally distributed and infect up to 400 million people each year and mainly spreading in the tropical region which covered the majority of the poverty countries such as south and southeast Asia and Africa. During the last 70 years, multiple epidemics have occurred, including epidemics of dengue virus and West Nile virus, and the most recent explosive epidemic of Zika virus in the Americas. To counter the Flavivirus infection, vaccine is the ultimately approach. Currently, commercially available licensed vaccines exist for five flaviviruses (YFV, DENV, JEV, KFDV and TBEV), and several others have been evaluated in preclinical and clinical studies. This Special Issue is focus on the flavivirus and flavivirus vaccine to understanding the pathogenesis and vaccine development for flavivirus

Guest Editor

Dr. Chao Shan

Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China

Deadline for manuscript submissions

closed (30 April 2022)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/102305

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).